Pemphigus vulgaris is an intraepidermal autoimmune mucocutaneous blistering disease whose etiopathogenesis includes various trigger factors, i.e., drugs and malignancies. We present a case of malignancy-exacerbated pemphigus vulgaris which required a careful diagnostic process in order to rule out paraneoplastic pemphigus, along with the challenges posed by the need of treating both cutaneous and oncologic diseases. Possible post-operative complications post-poned the start of first-line immunosuppressive treatment of pemphigus. Moreover, the infective risks had to be minimized during the peak of the COVID-19 pandemic in Italy. Intravenous immunoglobulins were chosen as “bridge” therapy before the tumor surgical excision, followed by rituximab in post-operative phase.
Case Report: Management of Malignancy-Exacerbated Pemphigus Vulgaris During COVID-19 Pandemic / Corra A.; Cammelli F.; Quintarelli L.; Barbato G.; Le Rose O.; Salemme A.; Di Zenzo G.; Coratti F.; Verdelli A.; Aimo C.; Mariotti E.B.; Bianchi B.; Cianchi F.; Caproni M.. - In: FRONTIERS IN MEDICINE. - ISSN 2296-858X. - ELETTRONICO. - 8:(2021), pp. 0-0. [10.3389/fmed.2021.708284]
Case Report: Management of Malignancy-Exacerbated Pemphigus Vulgaris During COVID-19 Pandemic
Cammelli F.;Quintarelli L.;Coratti F.;Verdelli A.;Aimo C.;Mariotti E. B.;Cianchi F.;Caproni M.
2021
Abstract
Pemphigus vulgaris is an intraepidermal autoimmune mucocutaneous blistering disease whose etiopathogenesis includes various trigger factors, i.e., drugs and malignancies. We present a case of malignancy-exacerbated pemphigus vulgaris which required a careful diagnostic process in order to rule out paraneoplastic pemphigus, along with the challenges posed by the need of treating both cutaneous and oncologic diseases. Possible post-operative complications post-poned the start of first-line immunosuppressive treatment of pemphigus. Moreover, the infective risks had to be minimized during the peak of the COVID-19 pandemic in Italy. Intravenous immunoglobulins were chosen as “bridge” therapy before the tumor surgical excision, followed by rituximab in post-operative phase.File | Dimensione | Formato | |
---|---|---|---|
fmed-08-708284.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
1.92 MB
Formato
Adobe PDF
|
1.92 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.